Do surface modifying additives (SMA) influence blood loss and thrombogenicity in conventional cardiopulmonary bypass for coronary artery bypass grafting?
Cardiopulmonary bypass (CPB) leads to activation of the coagulation and fibrinolytic cascades, partially associated with foreign surface contact. Hemorrhage and the need for blood products is associated with rising cost and increased risk of infection. Treatment with surface modifying additives (SMA) has been shown to reduce thrombogenicity and improve biocompatibility. 76 elective CABG-patients were randomly assigned to surface modifying additives (group I, n=39) or untreated circuits that were otherwise identical (group II, n=37). Measurements of coagulation activity and fibrinolysis, platelet count and function were made. The postoperative blood loss and blood product replacement was also assessed. Thrombin formation measured by prothrombin fragments 1+2 (5.7+/-0.4 nmol/l vs. 5.6+/-0.4 nmol/l), fibrinolytic activity measured by plasmin-antiplasmin complex (1752.6+/-216.8 microg/l vs.1180.0+/-74.8 microg/l) and the postoperative platelet count and function did not differ significantly between the two groups. Blood loss and transfusion requirements were slightly lower in the SMA group. The treatment of extracorporeal surfaces with surface modifying additives does not appear to reduce coagulation disorders and bleeding after conventional CPB.
Martens
S
S
Department of Thoracic and Cardiovascular Surgery, J. W. Goethe University, Frankfurt am Main, Germany. martens.herz@gmx.de
Matheis
G
G
Wimmer-Greinecker
G
G
Scherer
M
M
Doss
M
M
Moritz
A
A
D000368:Aged; D001777:Blood Coagulation / Q000187:drug effects; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D002315:Cardiopulmonary Bypass / Q000009:adverse effects* / Q000295:instrumentation; D001026:Coronary Artery Bypass / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D011446:Prospective Studies; D013499:Surface Properties; D013501:Surface-Active Agents / Q000627:therapeutic use; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*
D013501:Surface-Active Agents